Personalised medicine is a high-value field, expected to expand significantly over the coming years. Strong IP strategy is key to successfully protecting emerging innovations that hold the potential to transform lives.
The number of drug approvals in precision medicine is growing rapidly, yet this progress comes with significant legal and technical challenges. From navigating patent eligibility exclusions, to dealing with issues of ownership of data or divided infringement, while ensuring protection covers the constant evolution of assay platforms, good guidance is vital to success.
Working with leading universities, research charities and pioneering SMEs, HGF’s large personalised medicine team delivers patent drafting and prosecution, due diligence and freedom to operate programmes, along with management of transactional and contentious matters in this revolutionary field.
Our attorneys have a deep understanding of the challenges in this area. With extensive in-house experience, we are able to tap into genuine insights to lead our clients’ IP strategies and advise across multiple jurisdictions. HGF’s perspective as European attorneys can help to identify global opportunities for clients from across the globe.
HGF’s Partner Dr Markus Zoller is attending and speaking at the German Biotechnology days on 20th September 2021. German Biotechnology days is the go to event in the industry and …Event details
The IAM Patent 1000 – the world’s leading patent professionals 2021 guide has now been published. HGF has 18 European attorneys listed. IAM Patent 1000 is a unique guide that …Read article
Pharmaceutical and biotechnology patent applications also make top 10 most patented. Recent statistics published by the EPO show that a total of 14,295 European patent applications were filed in 2020 …Read article
How to streamline the trade mark selection process by conducting effective, in-house ‘dirty searches’. Selecting the right trade mark for your new healthcare product is a critically important task. Consumers …Read article
The 2021 EPO Guidelines provide much needed guidance on how to protect antibodies in Europe. Biological drugs including therapeutic antibodies have become increasingly important to the pharmaceutical industry. The European …Read article
Opportunities for additional pharmaceutical product patent protection in Europe, based on the use of a drug to treat a patient exhibiting a biomarker indicative of drug response. Recent years have …Read article
Exploring the growth of patents for connected medical devices, and how best to protect them. The Internet of Things (IoT) is expected to change our lives by creating a connected …Read article
To waive, or not to waive, that is the question. The earliest identified date of a patient presenting with symptoms of a “novel coronavirus” in Wuhan, China is reported to …Read article